Antifracture efficacy of long-term estrogens for osteoporosis.
D000368:Aged; D045930:Anabolic Agents / Q000627:therapeutic use; D000728:Androgens / Q000627:therapeutic use*; D004966:Estrogens, Conjugated (USP) / Q000627:therapeutic use*; D005260:Female; D005474:Fluoxymesterone / Q000627:therapeutic use; D006801:Humans; D008593:Menopause; D008777:Methyltestosterone / Q000627:therapeutic use; D008875:Middle Aged; D009277:Nandrolone / Q000627:therapeutic use; D009639:Norethandrolone / Q000627:therapeutic use; D010024:Osteoporosis / Q000188:drug therapy*; D010074:Oxandrolone / Q000627:therapeutic use; D010110:Oxymetholone / Q000627:therapeutic use; D013739:Testosterone / Q000627:therapeutic use; D013997:Time Factors
D045930:Anabolic Agents; D000728:Androgens; D004966:Estrogens, Conjugated (USP); D013739:Testosterone; D009277:Nandrolone; D010074:Oxandrolone; D005474:Fluoxymesterone; D010110:Oxymetholone; D009639:Norethandrolone; D008777:Methyltestosterone